Royalty Pharma

Live  

Royalty Pharma is a leading player in the biopharmaceutical industry, specializing in acquiring and managing revenue-producing intellectual property associated with pharmaceutical products. Founded in 1996, the company primarily focuses on purchasing royalty interests and product rights from biotechnology and pharmaceutical companies.
Royalty Pharma’s business model allows it to leverage existing drugs that are already on the market or in late-stage development, enabling it to generate revenue without the substantial costs and risks associated with drug development. The company has a diversified portfolio that includes royalties from a variety of therapeutic areas, such as oncology, neurology, and rare diseases.
In addition to its royalty acquisition activities, Royalty Pharma is engaged in partnerships with biopharmaceutical firms, providing them with upfront capital in exchange for a share of future revenues. The company is publicly traded and has grown significantly over the years through strategic acquisitions, strong financial management, and a focus on high-quality assets.
Royalty Pharma emphasizes its commitment to scientific innovation and the efficient delivery of healthcare solutions, while also maintaining a strong network of relationships within the industry, including collaborations with inventors and research institutions. The company is known for its financial strength, which allows it to pursue new opportunities in an evolving market.

Um95YWx0eS BQaGFybWEg aXMgYSBjb2 1wYW55IHRo YXQgaGVscH MgZGV2ZWxv cCBhbmQgc3 VwcG9ydCBt ZWRpY2luZX MuIEltYWdp bmUgaWYgdG hlcmUgd2Vy ZSBhIHJlYW xseSBjb29s IHRveSB0aG F0IG5lZWRl ZCBtb25leS B0byBiZSBk ZXNpZ25lZC BhbmQgbWFk ZS4gUm95YW x0eSBQaGFy bWEgZG9lcy Bzb21ldGhp bmcgc2ltaW xhciBidXQg Zm9yIG1lZG ljaW5lcyB0 aGF0IGhlbH AgcGVvcGxl IGZlZWwgYm V0dGVyLiBX aGVuIGEgbm V3IG1lZGlj aW5lIGlzIG NyZWF0ZWQs IGl0IHVzdW FsbHkgY29z dHMgYSBsb3 Qgb2YgbW9u ZXkgdG8gZG V2ZWxvcCwg d2hpY2ggY2 FuIGluY2x1 ZGUgcmVzZW FyY2gsIHRl c3RpbmcsIG FuZCBnZXR0 aW5nIGFwcH JvdmFsIGZy b20gaGVhbH RoIGF1dGhv cml0aWVzLj xicj5Ob3cs IGhlcmXigJ lzIGhvdyBS b3lhbHR5IF BoYXJtYSBt YWtlcyBtb2 5leTogdGhl eSBpbnZlc3 QgbW9uZXkg aW4gdGhlc2 UgbmV3IG1l ZGljaW5lcy BlYXJseSBv bi4gV2hlbi B0aGUgbWVk aWNpbmUgYm Vjb21lcyBz dWNjZXNzZn VsIGFuZCBz b2xkIHRvIH Blb3BsZSwg Um95YWx0eS BQaGFybWEg ZWFybnMgYS BwZXJjZW50 YWdlIG9mIH RoZSBtb25l eSBtYWRlIG Zyb20gdGhv c2Ugc2FsZX MuIEl04oCZ cyBsaWtlIG lmIHRoZXkg aGVscGVkIH NvbWVvbmUg Y3JlYXRlIG EgcG9wdWxh ciB0b3ksIH RoZXkgd291 bGQgZ2V0IG EgbGl0dGxl IGJpdCBvZi Btb25leSBl dmVyeSB0aW 1lIHRoYXQg dG95IHdhcy Bzb2xkLjxi cj5BcyBmb3 Igd2h5IFJv eWFsdHkgUG hhcm1hIGlz IHN1Y2Nlc3 NmdWwgYW5k IGxpa2VseS B0byBzdGF5 IHN1Y2Nlc3 NmdWwsIHRo ZXJlIGFyZS BhIGZldyBy ZWFzb25zLi BGaXJzdCwg dGhleSBwaW NrIHJlYWxs eSBwcm9taX NpbmcgbWVk aWNpbmVzIH RvIGludmVz dCBpbiwgd2 hpY2ggbWVh bnMgdGhleS BvZnRlbiBj aG9vc2UgdG hvc2UgdGhh dCBoYXZlIG EgZ29vZCBj aGFuY2UgdG 8gaGVscCBs b3RzIG9mIH Blb3BsZSBh bmQgbWFrZS Btb25leS4g U2Vjb25kLC B0aGV5IHdv cmsgd2l0aC BtYW55IGRp ZmZlcmVudC BraW5kcyBv ZiBtZWRpY2 luZXMsIHNv IHRoZXkgZG 9u4oCZdCBq dXN0IHJlbH kgb24gb25l LiBUaGlzIH ZhcmlldHkg aGVscHMgcH JvdGVjdCB0 aGVtIGlmIG 9uZSBtZWRp Y2luZSBkb2 VzbuKAmXQg ZG8gd2VsbC 4gRmluYWxs eSwgd2l0aC BtYW55IG5l dyBkaXNlYX NlcyB0aGF0 IG5lZWQgdH JlYXRtZW50 cyBhbmQgY2 9uc3RhbnQg cmVzZWFyY2 ggaGFwcGVu aW5nLCB0aG VyZSB3aWxs IGFsd2F5cy BiZSBuZXcg b3Bwb3J0dW 5pdGllcyBm b3IgUm95YW x0eSBQaGFy bWEgdG8gaW 52ZXN0IGlu IGFuZCBtYW tlIG1vbmV5 IGZyb20uIF RoYXTigJlz IHdoeSBtYW 55IHBlb3Bs ZSBiZWxpZX ZlIHRoZXkg d2lsbCBjb2 50aW51ZSB0 byBiZSBzdW NjZXNzZnVs IGluIHRoZS BmdXR1cmUh PGJyPg==

Um95YWx0eS BQaGFybWEg aXMgbm90YW JsZSBmb3Ig aXRzIHVuaX F1ZSBidXNp bmVzcyBtb2 RlbCBjZW50 ZXJlZCBhcm 91bmQgYWNx dWlyaW5nIG FuZCBtYW5h Z2luZyByZX ZlbnVlLWdl bmVyYXRpbm cgcGhhcm1h Y2V1dGljYW wgcm95YWx0 aWVzLiBUaG UgY29tcGFu eSBmb2N1c2 VzIG9uIGZ1 bmRpbmcgdG hlIGRldmVs b3BtZW50IG 9mIG5ldyBk cnVncyBieS BwdXJjaGFz aW5nIHJveW FsdHkgc3Ry ZWFtcyBmcm 9tIGRldmVs b3BlcnMgYW 5kIGNvbXBh bmllcyB0aG F0IGJyaW5n IGlubm92YX RpdmUgdGhl cmFwaWVzIH RvIHRoZSBt YXJrZXQuIF RoaXMgYWxs b3dzIHRoZW 0gdG8gZ2Vu ZXJhdGUgaW 5jb21lIHdp dGhvdXQgdG hlIHJpc2tz IGFzc29jaW F0ZWQgd2l0 aCBkcnVnIG RldmVsb3Bt ZW50LCBhcy B0aGV5IGRv IG5vdCBlbm dhZ2UgZGly ZWN0bHkgaW 4gcmVzZWFy Y2ggYW5kIG RldmVsb3Bt ZW50Ljxicj 5BZGRpdGlv bmFsbHksIF JveWFsdHkg UGhhcm1hIG hhcyBhIGRp dmVyc2UgcG 9ydGZvbGlv IHRoYXQgZW 5jb21wYXNz ZXMgdmFyaW 91cyB0aGVy YXBldXRpYy BhcmVhcywg aW5jbHVkaW 5nIG9uY29s b2d5LCBpbW 11bm9sb2d5 LCBhbmQgaW 5mZWN0aW91 cyBkaXNlYX Nlcywgd2hp Y2ggZW5oYW 5jZXMgaXRz IHJpc2sgZG l2ZXJzaWZp Y2F0aW9uLi BUaGUgY29t cGFueSBhbH NvIHBsYXlz IGEgcm9sZS BpbiBlbmFi bGluZyBiaW 90ZWNoIGFu ZCBwaGFybW FjZXV0aWNh bCBjb21wYW 5pZXMgdG8g YWNjZXNzIG NhcGl0YWws IHRodXMgZm FjaWxpdGF0 aW5nIHRoZS BhZHZhbmNl bWVudCBvZi BtZWRpY2Fs IHJlc2Vhcm NoIGFuZCBp bm5vdmF0aW 9uLjxicj5G dXJ0aGVybW 9yZSwgUm95 YWx0eSBQaG FybWEgaXMg cHVibGljbH kgdHJhZGVk IGFuZCBpcy Brbm93biBm b3IgaXRzIG ZpbmFuY2lh bCBzdHJlbm d0aCwgbWFr aW5nIGl0IG FuIGF0dHJh Y3RpdmUgaW 52ZXN0bWVu dCBmb3IgdG hvc2UgbG9v a2luZyBmb3 IgZXhwb3N1 cmUgdG8gdG hlIHBoYXJt YWNldXRpY2 FsIGluZHVz dHJ5IHdpdG hvdXQgdGhl IHZvbGF0aW xpdHkgdHlw aWNhbGx5IG Fzc29jaWF0 ZWQgd2l0aC BkcnVnIGRl dmVsb3BtZW 50IHN0b2Nr cy4gSXRzIG 1vZGVsIGhh cyBnYWluZW QgYXR0ZW50 aW9uIGFzIH RoZSBiaW9w aGFybWFjZX V0aWNhbCBz ZWN0b3IgY2 9udGludWVz IHRvIGV2b2 x2ZSwgaGln aGxpZ2h0aW 5nIHRoZSBp bXBvcnRhbm NlIG9mIGFs dGVybmF0aX ZlIGZ1bmRp bmcgbWVjaG FuaXNtcyB3 aXRoaW4gdG hlIGluZHVz dHJ5Ljxicj 4=

Um95YWx0eS BQaGFybWEg aXMgYSBiaW 9waGFybWFj ZXV0aWNhbC Bjb21wYW55 IHRoYXQgZm 9jdXNlcyBv biBhY3F1aX JpbmcgYW5k IG1hbmFnaW 5nIHJldmVu dWUtZ2VuZX JhdGluZyBw aGFybWFjZX V0aWNhbCBh bmQgYmlvdG VjaG5vbG9n eSBhc3NldH MuIEl0cyBw cmltYXJ5IG J1c2luZXNz IG1vZGVsIG ludm9sdmVz IHB1cmNoYX Npbmcgcm95 YWx0eSBpbn RlcmVzdHMg YW5kIHVsdH JhLXJhcmUg ZGlzZWFzZS Bhc3NldHMg ZnJvbSBvdG hlciBjb21w YW5pZXMuIF RoaXMgYWxs b3dzIHRoZW 0gdG8gZ2Vu ZXJhdGUgcm V2ZW51ZSBi YXNlZCBvbi B0aGUgc2Fs ZXMgb2YgdG hlc2UgZHJ1 Z3Mgd2l0aG 91dCB0aGUg YXNzb2NpYX RlZCBjb3N0 cyBvZiByZX NlYXJjaCBh bmQgZGV2ZW xvcG1lbnQs IG1hbnVmYW N0dXJpbmcs IG9yIG1hcm tldGluZy48 YnI+VGhleS B0eXBpY2Fs bHkgZW50ZX IgaW50byBh Z3JlZW1lbn RzIHdpdGgg ZHJ1ZyBkZX ZlbG9wZXJz LCBpbmNsdW RpbmcgbWFq b3IgcGhhcm 1hY2V1dGlj YWwgY29tcG FuaWVzIGFu ZCBzbWFsbG VyIGJpb3Rl Y2ggZmlybX MsIHRvIGFj cXVpcmUgYS BwZXJjZW50 YWdlIG9mIH RoZSBmdXR1 cmUgc2FsZX Mgb2YgdGhl aXIgcHJvZH VjdHMuIFRo aXMgY2FuIG luY2x1ZGUg ZXN0YWJsaX NoZWQgYmxv Y2tidXN0ZX IgZHJ1Z3Mg YXMgd2VsbC BhcyBlbWVy Z2luZyB0aG VyYXBpZXMg aW4gdmFyaW 91cyBzdGFn ZXMgb2YgZG V2ZWxvcG1l bnQuIEJ5IG RpdmVyc2lm eWluZyB0aG VpciBwb3J0 Zm9saW8gYW Nyb3NzIG51 bWVyb3VzIH Byb2R1Y3Rz IGFuZCB0aG VyYXBldXRp YyBhcmVhcy wgUm95YWx0 eSBQaGFybW EgbWl0aWdh dGVzIHJpc2 sgYW5kIGNh cGl0YWxpem VzIG9uIHRo ZSBncm93dG ggcG90ZW50 aWFsIG9mIG lubm92YXRp dmUgdHJlYX RtZW50cy48 YnI+QWRkaX Rpb25hbGx5 LCB0aGUgY2 9tcGFueSBt YXkgYWxzby BlbmdhZ2Ug aW4gZmluYW 5jaW5nIGFy cmFuZ2VtZW 50cywgc3Vj aCBhcyBzdH J1Y3R1cmlu ZyBjb250aW 5nZW50IHBh eW1lbnRzIG Jhc2VkIG9u IGZ1dHVyZS BzYWxlcyBt aWxlc3Rvbm VzLiBCeSBs ZXZlcmFnaW 5nIHRoZWly IGV4cGVydG lzZSBpbiB0 aGUgcGhhcm 1hY2V1dGlj YWwgbWFya2 V0IGFuZCBj YXBpdGFsaX ppbmcgb24g YXR0cmFjdG l2ZSBpbnZl c3RtZW50IG 9wcG9ydHVu aXRpZXMsIF JveWFsdHkg UGhhcm1hIG FpbXMgdG8g cHJvdmlkZS ByZXR1cm5z IHRvIGl0cy BpbnZlc3Rv cnMgd2hpbG Ugc3VwcG9y dGluZyB0aG UgY29udGlu dWVkIGRldm Vsb3BtZW50 IG9mIGltcG 9ydGFudCBo ZWFsdGhjYX JlIHNvbHV0 aW9ucy48Yn I+

AI can potentially pose a threat to Royalty Pharma’s products, services, and competitive positioning in various ways, although the extent of these threats may vary based on how the company adapts to advancements in technology.
1. Substitution: AI may enable the development of new therapies or drug discovery methods that could provide competitive alternatives to the products that Royalty Pharma has backed. If AI accelerates the creation of novel therapeutics or enhances the effectiveness of existing treatments, these innovations could compete directly with the portfolio of drugs for which Royalty Pharma holds royalties.
2. Disintermediation: AI technology might streamline drug development processes and lead to changes in how pharmaceuticals are commercialized. For example, the rise of direct-to-consumer models and AI-driven platforms could reduce the need for traditional intermediaries, potentially impacting Royalty Pharma’s business model, especially if newer companies bypass traditional royalty structures altogether.
3. Margin Pressure: The integration of AI into various aspects of pharmaceutical development and marketing can lead to increased efficiency, reduced costs, and enhanced productivity for competitors. If rivals who adopt AI technologies succeed in lowering their operating costs or improving their product offerings, this could exert margin pressure on Royalty Pharma, especially if the company is slower to adapt to these technological advancements.
Overall, while AI presents certain risks to Royalty Pharma, it also offers opportunities for enhanced efficiencies and improved decisiomaking in drug investment and royalty management. How the company responds to these AI-related challenges will be crucial in determining its competitive positioning in the healthcare sector.

Royalty Pharma’s earnings, cash flow, and valuation are particularly sensitive to changes in interest rates due to several factors:
1. Cost of Capital: Higher interest rates increase the cost of debt. If Royalty Pharma finances acquisitions or operations through debt, rising rates can lead to increased interest expenses, thereby reducing net earnings and cash flow.
2. Discount Rate: Valuations of companies, especially those reliant on future cash flows, are sensitive to the discount rate used in discounted cash flow (DCF) models. As interest rates rise, the discount rate typically increases, which can lower the present value of future cash flows, negatively impacting the valuation of Royalty Pharma.
3. Opportunity Cost: As interest rates rise, investors may seek safer investments, such as bonds, which become more attractive compared to equities. This shift can lead to a decrease in demand for Royalty Pharma’s stock, affecting its market valuation.
4. Pharmaceutical Industry Dynamics: Royalty Pharma’s business model relies on securing royalties from pharmaceutical products. If interest rates increase, it may result in costlier financing for research and development in the pharmaceutical industry, potentially delaying or reducing the number of successful drug developments. This could ultimately impact the cash flows derived from royalty agreements.
5. Judgment on Future Growth: Higher interest rates may slow overall economic growth, which can impact healthcare spending and the demand for pharmaceuticals. If public and private payers adjust their spending in response to economic conditions, this could directly affect Royalty Pharma’s revenues.
In summary, Royalty Pharma’s financial metrics and valuation are closely linked to interest rates through mechanisms such as cost of capital, discount rates, investor behavior, and the broader economic environment affecting the pharmaceutical industry.

U2V2ZXJhbC BzY2VuYXJp b3MgY291bG QgcG90ZW50 aWFsbHkgaW 1wYWlyIFJv eWFsdHkgUG hhcm1h4oCZ cyBlY29ub2 1pY3Mgb3Zl ciB0aGUgbm V4dCAz4oCT NSB5ZWFycy wgYnV0IG9u ZSBwYXJ0aW N1bGFybHkg Y29uY2Vybm luZyBzaXR1 YXRpb24gd2 91bGQgYmUg YSBzaWduaW ZpY2FudCBh bmQgc3VzdG FpbmVkIHJl ZHVjdGlvbi BpbiB0aGUg YXBwcm92YW wgcmF0ZXMg b3Igc2FsZX Mgb2YgZHJ1 Z3MgZm9yIH doaWNoIHRo ZSBjb21wYW 55IGhhcyBh Y3F1aXJlZC Byb3lhbHRp ZXMuIFRoaX MgY291bGQg YmUgY2F1c2 VkIGJ5IGEg Y29tYmluYX Rpb24gb2Yg ZmFjdG9ycy BzdWNoIGFz IHJlZ3VsYX RvcnkgY2hh bmdlcywgaW 5jcmVhc2Vk IGNvbXBldG l0aW9uIGZy b20gZ2VuZX JpY3MsIGEg c2xvd2Rvd2 4gaW4gdGhl IGRydWcgZG V2ZWxvcG1l bnQgcGlwZW xpbmUsIG9y IGEgbWFqb3 IgcHVibGlj IGhlYWx0aC BjcmlzaXMg dGhhdCBzaG lmdHMgZm9j dXMgYW5kIG Z1bmRpbmcg YXdheSBmcm 9tIGNlcnRh aW4gdGhlcm FwZXV0aWMg YXJlYXMuID xicj5JbiB0 aGlzIHNjZW 5hcmlvLCB0 aGUgY29tcG FueeKAmXMg bWFyZ2lucy Bjb3VsZCBl eHBlcmllbm NlIGEgc2hh cnAgZGVjbG luZSBkdWUg dG8gZGVjcm Vhc2VkIHJv eWFsdHkgcm V2ZW51ZXMs IGxlYWRpbm cgdG8gbG93 ZXIgcHJvZm l0YWJpbGl0 eS4gVGhlIH JlZHVjZWQg c2FsZXMgd2 91bGQgZGly ZWN0bHkgaW 1wYWN0IGNh c2ggZmxvdy wgY2F1c2lu ZyBhIHBvdG VudGlhbCBj YXNoIGNydW 5jaC4gSWYg dGhlIGNvbX BhbnkgcmVs aWVzIGhlYX ZpbHkgb24g cmVmaW5hbm Npbmcgb3Ig bmV3IGRlYn QgdG8gc3Vz dGFpbiBpdH Mgb3BlcmF0 aW9ucyBkdX JpbmcgdGhp cyBkb3dudH VybiwgaXQg bWlnaHQgcm VzdWx0IGlu IGEgaGVhdm llciBmaW5h bmNpYWwgYn VyZGVuLCBp bmNyZWFzaW 5nIGludGVy ZXN0IGV4cG Vuc2VzIGFu ZCBsaW1pdG luZyBpbnZl c3RtZW50cy BpbiBmdXR1 cmUgcHJvam VjdHMuPGJy PlRoZSBiYW xhbmNlIHNo ZWV0IHdvdW xkIGxpa2Vs eSByZWZsZW N0IGEgd2Vh a2VuZWQgcG 9zaXRpb24s IHdpdGggcG 90ZW50aWFs IGFzc2V0IG ltcGFpcm1l bnRzIHJlbG F0ZWQgdG8g cm95YWx0eS BhZ3JlZW1l bnRzIHRoYX QgYXJlIHVu ZGVycGVyZm 9ybWluZyBv ciBoYXZlIG 5vdCBtZXQg dGhlIGFudG ljaXBhdGVk IHJlZ3VsYX RvcnkgYXBw cm92YWwgdG ltZWxpbmVz LiBJbmNyZW FzZWQgbGV2 ZXJhZ2UgZH VlIHRvIHJp c2luZyBkZW J0IGxldmVs cyBjb3VsZC BkZXRlcmlv cmF0ZSBmaW 5hbmNpYWwg cmF0aW9zLC BtYWtpbmcg aXQgaGFyZG VyIGZvciBS b3lhbHR5IF BoYXJtYSB0 byByYWlzZS BhZGRpdGlv bmFsIGNhcG l0YWwgb3Ig aW52ZXN0IG luIG5ldyBv cHBvcnR1bm l0aWVzLjxi cj5PdmVyYW xsLCB0aGUg Y29tYmluYX Rpb24gb2Yg ZGltaW5pc2 hlZCByZXZl bnVlIHN0cm VhbXMsIHRp Z2h0ZW5lZC BtYXJnaW5z LCBjb25zdH JhaW5lZCBj YXNoIGZsb3 csIGFuZCBh IHBvdGVudG lhbGx5IHdl YWtlciBiYW xhbmNlIHNo ZWV0IGNvdW xkIHBvc2Ug c2VyaW91cy Bsb25nLXRl cm0gY2hhbG xlbmdlcyBm b3IgUm95YW x0eSBQaGFy bWHigJlzIG J1c2luZXNz IG1vZGVsIG FuZCBzdXN0 YWluYWJpbG l0eSBpbiB0 aGUgbWFya2 V0Ljxicj4=

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvQW lIaGVaYjRx bklaOXkzQn UwODAud2Vi cCIgYWx0PS JSb3lhbHR5 IFBoYXJtYS IgdGl0bGU9 IlJveWFsdH kgUGhhcm1h IiAgY2xhc3 M9ImltZy1m bHVpZCIgaG VpZ2h0PTUw IHdpZHRoPT UwIGxvYWRp bmc9J2xhen knIHN0eWxl PSdib3JkZX ItcmFkaXVz OiA2cHg7Jz 4KCiAgICAg ICAgICAgIC AgICAgICAg PGRpdiBzdH lsZT0nZmxl eDogMTsgdG V4dC1hbGln bjogY2VudG VyOyBtYXJn aW4tbGVmdD ogNXB4Oyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDxwIHN0 eWxlPSdmb2 50LXNpemU6 IDI2cHg7IG NvbG9yOiAj MzMzOyBtYX JnaW4tYm90 dG9tOiAxNX B4Oyc+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICDwn5OI IFdhbnQgdG 8gcmVhZCBt b3JlIGFib3 V0IFJveWFs dHkgUGhhcm 1hPwogICAg ICAgICAgIC AgICAgICAg ICAgICA8L3 A+CgogICAg ICAgICAgIC AgICAgICAg ICAgICA8YS BocmVmPSdp bmRleC5waH A/cGFnZT1z aWdudXAnIH N0eWxlPScK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIGJh Y2tncm91bm QtY29sb3I6 ICMwMDdCRk Y7CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC Bjb2xvcjog I2ZmZjsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIHBhZG Rpbmc6IDEw cHggMjBweD sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG JvcmRlci1y YWRpdXM6ID VweDsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIHRleHQt ZGVjb3JhdG lvbjogbm9u ZTsKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGZvbnQtd2 VpZ2h0OiBi b2xkOwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgbWFyZ2 luLXJpZ2h0 OiAxMHB4Ow ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgdH JhbnNpdGlv bjogYmFja2 dyb3VuZC1j b2xvciAwLj NzIGVhc2U7 JwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg b25tb3VzZW 92ZXI9J3Ro aXMuc3R5bG UuYmFja2dy b3VuZENvbG 9yPSIjMDA1 NmIzIicKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIG9ubW 91c2VvdXQ9 J3RoaXMuc3 R5bGUuYmFj a2dyb3VuZE NvbG9yPSIj MDA3QkZGIi c+CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC BTaWduIHVw IGZvciBmcm VlCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDwvYT 4KCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxzcG FuIHN0eWxl PSdtYXJnaW 46IDAgOHB4 OyBjb2xvcj ogIzU1NTsn Pm9yPC9zcG FuPgoKICAg ICAgICAgIC AgICAgICAg ICAgICAgPG EgaHJlZj0n aW5kZXgucG hwP3BhZ2U9 bG9naW4nIH N0eWxlPScK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIGNv bG9yOiAjMD A3QkZGOwog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgdGV4 dC1kZWNvcm F0aW9uOiB1 bmRlcmxpbm U7CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC Bmb250LXdl aWdodDogNT AwOyc+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBsb2cg aW4KICAgIC AgICAgICAg ICAgICAgIC AgICAgPC9h PgoKCiAgIC AgICAgICAg ICAgICAgIC AgICAgIDxw IHN0eWxlPS dtYXJnaW4t dG9wOiAxNX B4OyBmb250 LXNpemU6ID EzcHg7IGZv bnQtd2VpZ2 h0OiBib2xk OyBjb2xvcj ogI2QzMmYy ZjsnPgogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAg8J+Tli BHZXQgaW5z aWdodHMgZn JvbSA8aT4i VGhlIENoZW NrbGlzdCBW YWx1ZSBJbn Zlc3RvciDi gJQgQSBTbW FydGVyIFdh eSB0byBQaW NrIFN0b2Nr cyI8L2k+IG 5vdyEKICAg ICAgICAgIC AgICAgICAg ICAgICAgPC 9wPgoKICAg ICAgICAgIC AgICAgICAg ICAgICAgPC EtLQogICAg ICAgICAgIC AgICAgICAg ICAgICA8ZG l2IHN0eWxl PSdtYXJnaW 4tdG9wOiAx MnB4OyBmb2 50LXNpemU6 IDEzcHg7IG NvbG9yOiAj NDQ0Oyc+Ci AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICBTaW duIHVwIG5v dyBhbmQgZ2 V0IG91ciBm cmVlIGVCb2 9rIAogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGI+VGhl IENoZWNrbG lzdCBWYWx1 ZSBJbnZlc3 RvciDigJQg QSBTbWFydG VyIFdheSB0 byBQaWNrIF N0b2Nrczwv Yj4KICAgIC AgICAgICAg ICAgICAgIC AgICAgPC9k aXY+CiAgIC AgICAgICAg ICAgICAgIC AgICAgIC0t PgogICAgIC AgICAgICAg ICAgICAgIC AgICA8IS0t CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDxkaXYg c3R5bGU9J2 1hcmdpbi10 b3A6IDE2cH g7IGZvbnQt c2l6ZTogMT RweDsgY29s b3I6ICM0ND Q7IGZvbnQt ZmFtaWx5Oi AtYXBwbGUt c3lzdGVtLC BCbGlua01h Y1N5c3RlbU ZvbnQsIFNl Z29lIFVJLC BSb2JvdG8s IEhlbHZldG ljYSBOZXVl LCBzYW5zLX NlcmlmOyBs aW5lLWhlaW dodDogMS42 Oyc+CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICBIYXZlIH lvdSBoZWFy ZCBhYm91dC BvdXIgc2hv cnQgPHN0cm 9uZyBzdHls ZT0nZm9udC 13ZWlnaHQ6 IDYwMDsnPk RhaWx5IFZp ZGVvIE5ld3 NsZXR0ZXI8 L3N0cm9uZz 4/CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC A8YSBocmVm PSdodHRwcz ovL3d3dy5p bnNpZ2h0Zn VsdmFsdWUu Y29tL25ld3 NsZXR0ZXIu cGhwJyB0YX JnZXQ9J19i bGFuaycgc3 R5bGU9J2Nv bG9yOiAjMD A3QkZGOyB0 ZXh0LWRlY2 9yYXRpb246 IG5vbmU7IG ZvbnQtd2Vp Z2h0OiA1MD A7IG1hcmdp bi1sZWZ0Oi A2cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICBGaW5kIG 91dCBtb3Jl CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICA8 L2E+CiAgIC AgICAgICAg ICAgICAgIC AgICAgIDwv ZGl2PgogIC AgICAgICAg ICAgICAgIC AgICAgICAt LT4KICAgIC AgICAgICAg ICAgICAgIC A8L2Rpdj4K ICAgICAgIC AgICAgICAg IDwvZGl2Pg ogICAgICAg ICAgICA8L2 Rpdj4KICAg ICAgICAgIC AgCiAgICAg ICAgCiAgIC AgICAgPHNw YW4gY2xhc3 M9J2JsdXJy ZWQtdGV4dC c+CiAgICAg ICAgICAgIF VtOTVZV3gw ZVMgQlFhR0 Z5YldFZyBh WE1nWVNCc1 pXIEZrYVc1 bklHbHUgZG 1WemRHMWxi biBRZ1ptbH liU0IwIGFH RjBJSE53Wl cgTnBZV3hw ZW1WeiBJR2 x1SUdGamNY IFZwY21sdV p5QnkgWlha bGJuVmxMVy BkbGJtVnlZ WFJwIGJtY2 djR2hoY20g MWhZMlYxZE dsaiBZV3dn Y205NVlXIH gwYVdWekxp QkkgWlhKbE lHRnlaUyBC emIyMWxJR2 x1IGRHVnla WE4wYVcgNW 5JR1poWTNS eiBJR0ZpYj NWMElIIFJv WlNCamIyMX cgWVc1NU9q eGljaiA0eE xpQkdiM1Z1 IFpHVmtJR2 x1SUQgRTVP VFk2SUZKdi BlV0ZzZEhr Z1VHIGhoY2 0xaElIZGgg Y3lCbGMzUm hZbSB4cGMy aGxaQ0JpIG VTQlFZV0pz YnkgQk1aV2 R2Y25KbCBk R0VnWVc1a0 lHIGhoY3lC emFXNWogWl NCbmNtOTNi aSBCcGJuUn ZJR0VnIGMy bG5ibWxtYV cgTmhiblFn Y0d4aCBlV1 Z5SUdsdUlI IFJvWlNCb1 pXRnMgZEdo allYSmxJRy BsdWRtVnpk RzFsIGJuUW djMlZqZEcg OXlManhpY2 o0eSBMaUJH YjJOMWN5IE J2YmlCeWIz bGggYkhScF pYTTZJRiBS b1pTQmpiMj F3IFlXNTU0 b0NaY3kgQn djbWx0WVhK NSBJR0oxYz JsdVpYIE56 SUcxdlpHVn MgSUhKbGRt OXNkbSBWek lHRnliM1Z1 IFpDQndkWE pqYUcgRnph VzVuSUhKdi BlV0ZzZEds bGN5IEJtY2 05dElIQm8g WVhKdFlXTm xkWCBScFky RnNJR052IG JYQmhibWxs Y3kgQnZiaU J6Y0dWaiBh V1pwWXlCa2 NuIFZuY3lC MGFHRjAgSU dGeVpTQmhi SCBKbFlXUj VJRzl1IElI Um9aU0J0WV ggSnJaWFFn YjNJZyBhVz RnYkdGMFpT IDF6ZEdGbl pTQmsgWlha bGJHOXdiVy BWdWRDNDhZ bkkrIE15NG dVRzl5ZEcg WnZiR2x2SU dScCBkbVZ5 YzJsMGVUIG 9nVW05NVlX eDAgZVNCUW FHRnliVyBF Z2FHRnpJR0 VnIFpHbDJa WEp6WlMgQn diM0owWm05 cyBhVzhnZE doaGRDIEJw Ym1Oc2RXUm wgY3lCeWIz bGhiSCBScF pYTWdabkp2 IGJTQjJZWE pwYjMgVnpJ SFJvWlhKaC BjR1YxZEds aklHIEZ5Wl dGekxDQnog ZFdOb0lHRn pJRyA5dVky OXNiMmQ1IE xDQnVaWFZ5 YjIgeHZaM2 tzSUdGdSBa Q0J5WVhKbE lHIFJwYzJW aGMyVnogTG lCVWFHbHpJ RyBScGRtVn ljMmxtIGFX TmhkR2x2Ym kgQm9aV3h3 Y3lCaSBZV3 hoYm1ObElI IEpwYzJzdV BHSnkgUGpR dUlFNXZkRy BGaWJHVWdZ V054IGRXbH phWFJwYjIg NXpPaUJVYU dVZyBZMjl0 Y0dGdWVTIE JvWVhNZ2JX RmsgWlNCem FXZHVhVyBa cFkyRnVkQ0 JoIFkzRjFh WE5wZEcgbH Zibk1nYjNa bCBjaUIwYU dVZ2VXIFZo Y25Nc0lHbH UgWTJ4MVpH bHVaeSBCeW IzbGhiSFJw IFpYTWdiMj RnYzIgOXRa U0J2WmlCMC BhR1VnWW1W emRDIDF6Wl d4c2FXNW4g SUdSeWRXZH pJRyBsdUlI Um9aU0IzIG IzSnNaQ3dn YzMgVmphQ0 JoY3lCSSBk VzFwY21Fc0 lFIFY1YkdW aExDQmggYm 1RZ1ZtVnlk RyBWNDRvQ1 pjeUJqIGVY TjBhV01nWm 0gbGljbTl6 YVhNZyBaSE oxWjNNdVBH IEp5UGpVdU lFbFEgVHpv Z1VtOTVZVy B4MGVTQlFh R0Z5IGJXRW dkMlZ1ZEMg QndkV0pzYV dNZyBhVzRn U25WdVpTIE F5TURJd0xD QnkgWVdsem FXNW5JRyBG d2NISnZlR2 x0IFlYUmxi SGtnSkQgSW dZbWxzYkds diBiaUJwYm lCcGRIIE1n YVc1cGRHbG ggYkNCd2RX SnNhVyBNZ2 IyWm1aWEpw IGJtY3VJRl JvYVggTWdi VzkyWlNCeS BaWEJ5WlhO bGJuIFJsWk NCaElITnAg WjI1cFptbG pZVyA1MElH MXBiR1Z6IG RHOXVaU0Jt YjMgSWdkR2 hsSUdOdiBi WEJoYm5rZ1 lXIDVrSUhC eWIzWnAgWk dWa0lHbDBJ SCBkcGRHZ2 dZV1JrIGFY UnBiMjVoYk MgQmpZWEJw ZEdGcyBJSF J2SUhCMWNu IE4xWlNCbW RYSjAgYUdW eUlHRmpjWC BWcGMybDBh Vzl1IGN5ND hZbkkrTmkg NGdVR0Z5ZE c1bCBjbk5v YVhCeklIIG RwZEdnZ1lt bHYgZEdWam FDQm1hWCBK dGN6b2dWR2 hsIElHTnZi WEJoYm4ga2 diMlowWlc0 ZyBZMjlzYk dGaWIzIEpo ZEdWeklIZH AgZEdnZ1lt bHZkRyBWam FDQmpiMjF3 IFlXNXBaWE 1zSUcgOW1a bVZ5YVc1bi BJSFJvWlcw Z2RHIGhsSU c5d2NHOXkg ZEhWdWFYUj VJSCBSdklH MXZibVYwIG FYcGxJSFJv WlcgbHlJR1 oxZEhWeSBa U0J5WlhabG JuIFZsSUhO MGNtVmggYl hNZ2QyaHBi RyBVZ2MzUn BiR3dnIGFX NTJaWE4wYV cgNW5JR2x1 SUhKbCBjMl ZoY21Ob0lH IEZ1WkNCa1 pYWmwgYkc5 d2JXVnVkQy A0OFluSStO eTRnIFJtbH VZVzVqYVcg RnNJSE4wY2 1WdSBaM1Jv T2lCU2IzIG xoYkhSNUlG Qm8gWVhKdF lTQm9ZWCBN Z1pHVnRiMj V6IGRISmhk R1ZrSUggTj BjbTl1WnlC bSBhVzVoYm 1OcFlXIHdn Y0dWeVptOX kgYldGdVky VXNJRyBOdm JuTnBjM1Js IGJuUnNlU0 JuWlcgNWxj bUYwYVc1bi BJSE4xWW5O MFlXIDUwYV dGc0lHTmgg YzJnZ1pteH ZkeSB3Z2Qy aHBZMmdnIF pXNWhZbXhs Y3kgQnBkQ0 IwYnlCeSBa V2x1ZG1Wem RDIEJwYmlC aFkzRjEgYV hKcGJtY2di VyA5eVpTQn liM2xoIGJI UnBaWE1nWV cgNWtJSEps ZEhWeSBiaU IyWVd4MVpT IEIwYnlCem FHRnkgWldo dmJHUmxjbi BNdVBHSnlQ amd1IElFTn ZiVzFwZEcg MWxiblFnZE c4ZyBhVzV1 YjNaaGRHIG x2YmpvZ1ZH aGwgSUdOdm JYQmhibiBu aWdKbHpJR2 x1IGRtVnpk RzFsYm4gUn pJR0Z5WlNC biBaV0Z5Wl dRZ2RHIDkz WVhKa2N5Qn AgYm01dmRt RjBhWCBabE lIUm9aWEpo IGNHbGxjeX dnYzMgVndj Rzl5ZEdsdS BaeUIwYUdV Z1pHIFYyWl d4dmNHMWwg Ym5RZ2IyWW dibSBWM0lI UnlaV0YwIG JXVnVkSE1n ZEcgaGhkQ0 JqWVc0ZyBj RzkwWlc1MG FXIEZzYkhr Z2FXMXcgY2 05MlpTQndZ WCBScFpXNT BJRzkxIGRH TnZiV1Z6TG ogeGljajQ1 TGlCVCBkSE p2Ym1jZ2JH IFZoWkdWeW MyaHAgY0Rv Z1VtOTVZVy B4MGVTQlFh R0Z5IGJXSG lnSmx6SUcg MWhibUZuWl cxbCBiblFn ZEdWaGJTIE JwYm1Oc2RX UmwgY3lCbG VIQmxjbSBs bGJtTmxaQ0 J3IGNtOW1a WE56YVcgOX VZV3h6SUda eSBiMjBnWW 05MGFDIEJt YVc1aGJtTn AgWVd3Z1lX NWtJSCBCb1 lYSnRZV05s IGRYUnBZMk ZzSUcgSmhZ MnRuY205MS BibVJ6TENC M2FHIGxqYU NCd2NtOTIg YVdSbGN5Qm hJSCBOMGNt OXVaeUJtIG IzVnVaR0Yw YVcgOXVJR1 p2Y2lCdCBZ V3RwYm1jZ2 FXIDVtYjNK dFpXUWcgYV c1MlpYTjBi VyBWdWRDQm taV05wIGMy bHZibk11UE cgSnlQakV3 TGlCVCBiMk 5wWVd3Z2Nt IFZ6Y0c5dW MybGkgYVd4 cGRIazZJRi BSb1pTQmpi MjF3IFlXNT VJR2x6SUcg RnNjMjhnYV c1MiBiMngy WldRZ2FXID RnY0docGJH RnUgZEdoeW IzQnBZeSBC bFptWnZjbl J6IExDQmpi MjUwY20gbG lkWFJwYm1j ZyBkRzhnY2 1WelpXIEZ5 WTJnZ1lXNW sgSUdSbGRt VnNiMyBCdF pXNTBJR2x1 IGFYUnBZWF JwZG0gVnpJ SFJvWVhRZy BjMlZsYXlC MGJ5IEJoWk dSeVpYTnog SUhWdWJXVj BJRyAxbFpH bGpZV3dnIG JtVmxaSE11 UEcgSnlQbF JvWlhObCBJ R1poWTNSek lHIGhwWjJo c2FXZG8gZE NCU2IzbGhi SCBSNUlGQm 9ZWEp0IFll S0FtWE1nZF cgNXBjWFZs SUhCdiBjMm wwYVc5dUlH IGx1SUhSb1 pTQncgYUdG eWJXRmpaWC BWMGFXTmhi Q0JwIGJuWm xjM1J0Wlcg NTBJR3hoYm 1SeiBZMkZ3 WlNCaGJtIF FnYVhSeklI TjAgY21GMF pXZHBZeSBC aGNIQnliMk ZqIGFDQjBi eUJuWlcgNW xjbUYwYVc1 biBJSEpsZG 1WdWRXIFVn ZEdoeWIzVm 4gYUNCeWIz bGhiSCBScF pYTXVQR0p5 IFBnPT0KIC AgICAgICA8 L3NwYW4+Ci AgICAgICAg CiAgICAgIC Ag